The Journal of Urology
Volume 183, Issue 4 , Pages 1598-1603, April 2010

Screening Agents for Preventive Efficacy in a Bladder Cancer Model: Study Design, End Points, and Gefitinib and Naproxen Efficacy

Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, and Departments of Genetics and Surgery, University of Alabama at Birmingham (MMJ, CJG), Birmingham, Alabama

Received 26 May 2009 published online 22 February 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Study received institutional animal care and use committee approval.

 Supported by National Cancer Institute Contract HHSN261200433001C.

PII: S0022-5347(09)03145-0

doi:10.1016/j.juro.2009.12.001

The Journal of Urology
Volume 183, Issue 4 , Pages 1598-1603, April 2010

Article Tools

* Image Usage & Resolution